1 week ago
Capricor Therapeutics (CAPR) Stock Plummets 70% Following FDA Concerns
Capricor Therapeutics (CAPR) stock crashed 70% after FDA raised concerns about modified trial endpoints and limited evidence for DMD heart therapy deramiocel.
The post Capricor Therapeutics (CAPR) Stock Plummets 70% Following FDA Concerns appeared first on Blockonomi.
Source: Blockonomi →Related News
- 9 hours ago
AbCellera (ABCL) Stock Surges 6% on Menopause Treatment Phase 2 Data Reveal
- 9 hours ago
Tempus AI (TEM) Stock Soars 11% on Groundbreaking Cancer AI Study and Quarterly...
- 9 hours ago
Uber (UBER) Stock Surges on Q2 Earnings Beat: Is the Rally Sustainable?
- 10 hours ago
QuantumScape (QS) Stock Surges 16.5% This Week Despite Lack of News
- 11 hours ago
Westwater Resources (WWR) Stock Soars 88% on $25M Federal Financing Deal